PDGFRβ and HIF-1α inhibition with imatinib and radioimmunotherapy of experimental prostate cancer

Kimura, Yu; Inoue, Kotaro; Abe, Michio; Nearman, Jessica; Baranowska‐Kortylewicz, Janina

doi:10.4161/cbt.6.11.4854

Cited by 16 publications

(13 citation statements)

References 49 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibroblasts can be activated by excessive PDGF released by tumor cells [27] and proliferate in a dose dependent manner with PDGF-BB (a subtype of PDGF) stimulation [28]. Since imatinib is regarded as an inhibitor of PDGFR-beta by blocking the phosphorylation of the receptor [12,29], it is postulated that the decrease of tumor IFP by SSL-IMA is related to the inhibition of tumor fibroblasts through blocking PDGF pathway. NIH/3T3 fibroblasts expressing PDGFR-beta [30] were used to investigate the effect of SSL-IMA in vitro.…”

Section: Inhibition Of Pdgfr-beta and Fibroblast Proliferationmentioning

confidence: 99%

The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin

Fan

et al. 2013

Biomaterials

View full text Add to dashboard Cite

Section: Inhibition Of Pdgfr-beta and Fibroblast Proliferationmentioning

confidence: 99%

The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin

Fan

et al. 2013

Biomaterials

View full text Add to dashboard Cite

“…It should be pointed out that the decrease of VEGF expression was identified predominantly related to the inhibition of c-Kit-induced HIF-1 activity in small cell lung cancer cells [67]. However, another study showed that imatinib inhibits HIF-1 expression in PC-3 tumors, thus improving radioimmunotherapy, and has a significant time-and dosedependent reduction in the expression of insulin-like growth factor-1 (IGF-1) but with no effect on VEGF [66]. The discrepancy in the results of imatinib on VEGF expression might be due to the use of different cell types and experimental conditions.…”

Section: Miscellaneousmentioning

confidence: 95%

“…Comparing these agents, it can be indicated that a benzoazaheterocyle, especially the quinazoline moiety, which is also the mother nuclear structrure of a class of receptor tyrosine kinase inhibitors (RTKIs), is indispensable for the antiangiogenic and anti-HIF properties of this class of compounds. And in this sense, other series of small-molecule RTKIs and monoclonal antibodies targeting VEGFR or EGFR may exhibit similar HIF-1 inhibiting activity and this is indeed the case, for example, imatinib [66], cetuximab and trastuzumab [69].…”

Section: Benzoazaheterocyclesmentioning

confidence: 99%

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

Wang¹,

Zhou

2011

CMC

View full text Add to dashboard Cite

The discovery of hypoxia-inducible factor-1 has led to a rapidly increasing understanding of the molecular mechanism of tumor hypoxia in the past two decades. Today it is generally accepted that HIF-1 plays a pivotal role in the cellular response to tumor hypoxia which represents a major obstacle to the success of radiotherapy and chemotherapy. Meanwhile, many details involved in the expression, accumulation and transactivation of HIF-1 have been well elucidated. Targeting HIF-1 has become a novel and efficient strategy for cancer therapy and a number of agents have been developed aiming to suppress HIF-1. This review will concisely introduce the general knowledge on the molecular biology of HIF-1 and possible targets along the HIF-1 pathway. Moreover, a number of compounds reported with anti-HIF-1 activity are included and mainly classified as direct and indirect inhibitors based on their different modes of action. While direct HIF-1 inhibitors prevent HIF-1 from transactivation, DNA binding and subsequently initiating transcriptional activity, indirect HIF-1 inhibitors generally block the transcription or translation of HIF-1α or promote the degradation of HIF-1α protein. According to different structural features, direct HIF-1 inhibitors are divided into several groups: polyamides, quinols and naphthoquinone spiroketal analogues, shikonin derivatives, epidithiodiketopiperazines, and two representative drugs: echinomycin and bortezomib. In the same way, indirect inhibitors comprise the following classes: polyphenols, benzoazaheterocycles, rapamycins, camptothecins, geldanamycins, (aryloxyacetylamino)benzoic acid analogues, 2-methoxyestradiol and analogues, hydroxamic acid compounds and others. The rest with mechanism still not so clear would also be listed and introduced, with an emphasis on the marinederived natural products. The in vitro and/or in vivo activities of these compounds and their mechanisms of HIF-1 inhibition would be discussed and the SARs of unique structural types of HIF-1 inhibitors will be briefly concluded.

show abstract

“…The development of improved therapy modalities should therefore be prioritized and targeted therapies based on TNPs are promising candidates to increase the therapeutic efficacy and chance for survival of this category of patients. Several studies of the therapeutic efficacy and toxicity of RIT against PCa have been performed [492,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544]. …”

Section: The Prostate Cancer Casementioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

PDGFRβ and HIF-1α inhibition with imatinib and radioimmunotherapy of experimental prostate cancer

Cited by 16 publications

References 49 publications

The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin

The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About